Strides Pharma Science obtains USFDA approval for Ursodiol capsules
Category: #headlines |   By Pankaj Singh |   Date: 2021-01-27  | 
  • Share
  • Twitter
  • Facebook
  • LinkedIn

Strides Pharma Science obtains USFDA approval for Ursodiol capsules

Strides Pharma Science Ltd., a leading manufacturer of soft gelatin capsules, has reportedly received a green light from the health regulator USFDA (United States Food and Drug Administration) for commercializing generic Ursodiol capsules which will be used in treating PBC (Primary Biliary Cirrhosis) in America.

Credible sources cited that the company's wholly-owned division, Strides Pharma Global Pte Ltd., Singapore, has received approval from the US FDA for marketing Ursodiol capsules in 300mg. The company said that its product is bioequivalent and therapeutically equivalent to the Actigall capsules developed by Allergan.

Strides Pharma Global added that the product will be developed at the pharma firm’s Bengaluru facility and will be commercialized by Strides Pharma Inc. in the United States.

It is worth noting that Ursodiol capsules USP 400 Mg is worth USD 45 million in the U.S. market, as claimed in the November 2020 data published by IQVIA. In the previous week, the drug firm was granted permission from the U.S. regulator for the use of Emtricitabine and Tenofovir Disoproxil Fumarate tablets for treating patients suffering from HIV, cited sources knowledgeable with the matter.

According to reliable sources, Strides Pharma has a total of 127 new drug application filings with USFDA of which 96 have already been approved, whereas 31 are pending approval. The company’s stock has increased significantly by 12% over the last three months, however, inconsistent financials remain a concern, cite reliable sources.

About Strides Pharma Science Limited

Founded in 1990 by Arun Kuma, Strides Shasun Limited, later renamed Strides Pharma Science Limited, is a pharmaceutical organization based in Bangalore, India. Strides Pharma is primarily involved in the development of IP-based niche finished dosage formulations and mainly operates in regulated markets of Australia, the U.S., Europe, and Canada. It boasts of a team of 2500 people across seven global manufacturing sites, five of which are USFDA approved facilities.

Source Credits –

https://www.moneycontrol.com/news/trends/health-trends/strides-pharma-gets-usfda-nod-for-generic-drug-6393071.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with...

Read More

More News By Pankaj Singh

Reliance Industries planning to enter India’s digital payments market
Reliance Industries planning to enter India’s digital payments market
By Pankaj Singh

Amidst the booming digital payments market, Indian multinational conglomerate Reliance Industries Ltd. is reportedly joining forces with American tech giants such as Facebook Inc. and Google LLC as well as with financial technology company Infibeam, ...

Aurora to reduce laser LiDAR costs through OURS Technology acquisition
Aurora to reduce laser LiDAR costs through OURS Technology acquisition
By Pankaj Singh

Leading autonomous driving tech developer Aurora Innovation has acquired OURS Technology Inc., a Silicon Valley-based tech firm. Sources aware of the development stated that the acquisition will allow Aurora to cut costs as well as the size of LiDAR ...

Flipkart teams up with Mahindra, Hero to deploy 25,000 EVs in India
Flipkart teams up with Mahindra, Hero to deploy 25,000 EVs in India
By Pankaj Singh

Bengaluru-based e-commerce company Flipkart is planning to deploy over 25,000 electric vehicles across its delivery network in India, in line with its recent commitment to transition to electric mobility by 2030. Sources close to the matter claimed ...